Thermo Fisher Scientific Inc. (NYSE:TMO) Stock Holdings Increased by Regency Capital Management Inc. DE

Regency Capital Management Inc. DE increased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 40.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,974 shares of the medical research company's stock after acquiring an additional 2,860 shares during the period. Thermo Fisher Scientific comprises 3.0% of Regency Capital Management Inc. DE's investment portfolio, making the stock its 13th biggest holding. Regency Capital Management Inc. DE's holdings in Thermo Fisher Scientific were worth $4,963,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the stock. Norges Bank purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth about $3,149,754,000. GAMMA Investing LLC grew its position in shares of Thermo Fisher Scientific by 60,610.9% during the 1st quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company's stock valued at $1,203,859,000 after purchasing an additional 2,415,346 shares in the last quarter. T. Rowe Price Investment Management Inc. increased its holdings in shares of Thermo Fisher Scientific by 86.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,083,900 shares of the medical research company's stock worth $1,604,338,000 after purchasing an additional 1,433,444 shares during the period. Kovitz Investment Group Partners LLC raised its position in shares of Thermo Fisher Scientific by 1,905.4% in the fourth quarter. Kovitz Investment Group Partners LLC now owns 903,232 shares of the medical research company's stock worth $469,889,000 after buying an additional 858,193 shares in the last quarter. Finally, Grantham Mayo Van Otterloo & Co. LLC increased its stake in Thermo Fisher Scientific by 140.7% in the 4th quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 1,093,866 shares of the medical research company's stock worth $569,062,000 after acquiring an additional 639,467 shares during the last quarter. Institutional investors own 89.23% of the company's stock.

Insider Activity at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the transaction, the executive vice president directly owned 23,167 shares in the company, valued at $9,960,188.31. This trade represents a 1.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Trading Up 5.6%

NYSE TMO traded up $22.87 on Tuesday, reaching $427.81. The stock had a trading volume of 3,672,095 shares, compared to its average volume of 2,032,441. The firm has a market capitalization of $161.49 billion, a price-to-earnings ratio of 25.09, a P/E/G ratio of 2.21 and a beta of 0.77. The company has a quick ratio of 1.38, a current ratio of 1.77 and a debt-to-equity ratio of 0.64. The stock has a fifty day moving average price of $410.38 and a two-hundred day moving average price of $472.32. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $5.10 by $0.05. The company had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The firm's revenue was up .2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $5.11 earnings per share. As a group, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.40%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is presently 10.09%.

Wall Street Analysts Forecast Growth

TMO has been the topic of several recent analyst reports. Wells Fargo & Company cut their target price on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating on the stock in a report on Thursday, April 24th. Evercore ISI dropped their target price on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a report on Tuesday, July 8th. Robert W. Baird dropped their target price on shares of Thermo Fisher Scientific from $573.00 to $553.00 and set an "outperform" rating on the stock in a report on Friday. Royal Bank Of Canada decreased their target price on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Finally, The Goldman Sachs Group set a $610.00 price objective on shares of Thermo Fisher Scientific and gave the company a "buy" rating in a research report on Wednesday, April 23rd. Four analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $599.30.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.